Patient and Provider Opportunities
The Hepatitis B Foundation is pleased to share information about current and upcoming opportunities for people living with hepatitis B and\or D and their providers. These opportunities can be tools and resources, clinical trials, or other research opportunities to learn more from people who have hepatitis B or coinfection with delta.
GSK is launching a new clinical trial called B-United, which will test a study drug called daplusiran/tomligisiran (DAP/TOM) followed by another study drug called bepirovirsen as a potential new treatment for chronic hepatitis B virus infection
DAP/TOM is designed to reduce the amount of a viral protein called hepatitis B surface antigen (HBsAg) in your blood. Bepirovirsen is designed to further lower the level of HBsAg and stop the virus from making it, which might allow the immune system to control the virus.This therapy is not currently approved for treating chronic hepatitis B virus infection. However, the study drugs have been given to adults in other studies.
By reducing HBsAg levels using DAP/TOM before starting treatment with bepirovirsen, we may be able to make bepirovirsen more effective at treating hepatitis B. The B-United study is part of the effort to develop treatments that may lead to a functional cure in some patients. This could mean that these patients would no longer need treatment for their disease.
You may be eligible to participate in the B-United study if you:
-
Are at least 18 years old (the minimum age may be higher in some countries);
-
Have had diagnosed chronic hepatitis B infection for at least six months;
-
Have been on stable nucleoside/nucleotide analogue (NA) treatment (sometimes referred to as antivirals, such as tenofovir or entecavir) for the past 6 months, without any changes for the past 3 months.
If eligible for the study, you will continue NA treatment and receive an investigational therapy that consists of:
1) daplusiran/tomligisiran OR placebo for 24 weeks
followed by
2) bepirovirsen for 24 weeks
Following study treatment with daplusiran/tomligisiran (or placebo) and bepirovirsen, you will continue your NA treatment for 24 more weeks. The study doctor will then determine if you can stop your NA treatment and, if so, you will be off-NA treatment for up to 28 weeks while closely monitored by the study doctor.
Clinical trials provide a great opportunity to help advance hepatitis B research and give people with hepatitis B access to new treatments. To find out more information and see if you might be eligible, please visit www.BUnitedStudy.com.
Survey: Seeking youth & adolescent perspectives on hepatitis B
The Hepatitis B Foundation wants to learn about the experiences of young people with hepatitis B to improve care and support. If you or someone you know is a youth with hepatitis B, you can participate in a brief screening survey. Your insights will help inform clinicians and healthcare professionals about the unique needs of youth and adolescents.
Please sign up to participate here.
Questions? Reach out to Catherine.Freeland@hepb.org. Thank you for helping us make a difference!
Survey: Future hepatitis B treatment
Are you age 18 or over and living with hepatitis B and interested in sharing your thoughts on future treatment? The Hepatitis B Foundation wants to know what you think about different strategies for possible future administration of hepatitis B treatment.
Your responses to our anonymous online survey will help inform future drug development for hepatitis B. We would like as many people as possible to complete the survey!
All responses will be kept anonymous and confidential. The 20-minute survey is available in English, Tagalog, Mandarin, Spanish, and Arabic. Please click one of the languages to complete the survey in the language of your choice. If you have any questions, please email Yasmin Ibrahim at Yasmin.Ibrahim@hepb.org. Thank you for your help!
Survey: COVID-19 vaccine perspectives
Please consider contributing your time and experience to an important study that focuses on underrepresentation of specific populations in clinical trials for the COVID-19 vaccine!
- What’s the study about? We want to gain an understanding about the factors that influenced your willingness to receive the COVID-19 vaccine, and how different information sources impacted your decision to get vaccinated or not.
- Eligibility: Age 18 or older – including people living with hepatitis B and those who are not infected with hep B – who live in African, Southeast Asian, Western Pacific (AAPI), or Latin American countries and U.S. residents of African, Southeast Asian, Western Pacific (AAPI), or Latin American origin.
- Survey details: Your responses will be anonymous, and the survey takes less than 25 minutes!
Your insights will help public health and research organizations develop effective communication strategies tailored for your community, which can help enhance inclusion and diversity in future drug development studies!
Hepatitis delta research opportunity
If you are living with hepatitis delta, are at least 18 years old, and live in the United States, Mongolia, Algeria, Morocco, or Argentina, you are invited to participate in a new research opportunity! IQVIA and the Hepatitis B Foundation want to better understand the experience of living with hepatitis delta, including signs, symptoms, and impacts, to ensure that the voices of those with lived experience are included in the development of clinical trials and clinical management. This study does NOT include any treatment and will simply involve a 60-minute phone interview. You will receive compensation for your time! Share your story today - email contact@global-patients.com.
Disclaimer – The opportunities listed on this page do not represent all available opportunities. The Hepatitis B Foundation receives funding to provide information about the specific opportunities listed on this page. The Hepatitis B Foundation follows IRB-approved protocols and our own Corporate Ethics Policy for all listings. If you are interested in having an opportunity listed on this page, please email info@hepb.org.